Wednesday, October 12, 2016

Gee's Linctus BP (BOOTS COMPANY PLC)





1. Name Of The Medicinal Product



Opiate Squill Linctus BP/Gee's Linctus BP


2. Qualitative And Quantitative Composition












Active ingredients




% v/v




Opium Tincture BP




1.67




Squill Vinegar for Oxymel




10.0




(Equivalent to squill oxymel



camphorated opium tincture)




33.3



33.3



3. Pharmaceutical Form



Oral solution.



4. Clinical Particulars



4.1 Therapeutic Indications



For the symptomatic relief of chesty cough.



4.2 Posology And Method Of Administration



For oral administration.



Adults and children over 12 years



5ml three to four times daily.



Children under 12 years



Not recommend for children under 12 years unless prescribed by a physician.



Elderly



There is no need for dosage reduction in the elderly.



4.3 Contraindications



Hypersensitivity to ingredients. Patients with impaired renal or hepatic function or cardiac disorders. Moderate to severe respiratory depression, acute alcoholism, convulsive disorders, head injuries and conditions in which there is raised intracranial pressure.



4.4 Special Warnings And Precautions For Use



Should be used with caution in patients with colitis as there is risk of precipitating toxic megacolon. Should be used with caution in elderly patients as there is a risk of percipitating faecal impaction and intestinal obstruction. Excessive, long term use could induce dependence.



Warning: Do not exceed the stated dose.



If symptoms persist, consult your doctor.



Keep all medicines out of the reach of children.



May cause drowsiness.



This medicinal product contains 60.2g of sucrose. When taken according to the dosage recommendations each 5ml dose supplies up to 1.5g of sucrose. Unsuitable in hereditary fructose intolerance, glucose-galactose malabsorption syndrome or sucrase–isomaltase deficiency. (Sucrose)



Warning: this product contains 18.9% by volume of ethanol.



Each 5ml dose contains 0.76g of alcohol.



Harmful for those suffering from liver disease, alcoholism, epilepsy, brain injury or disease as well as for pregnant women and children.



May modify or increase the effect of other medicines. (Alcohol)



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



Clinically significant interactions may occur in patients taking MAOI's concurrently or within 14 days of such treatment and these reactions may be serious. The depressant effects of morphine may enhance depressants of the central nervous system such as alcohol, anaesthetics, hypnotics, sedatives and phenothiazines.



4.6 Pregnancy And Lactation



The safety of this product during pregnancy and lactation has not been established.



4.7 Effects On Ability To Drive And Use Machines



Opiate Squill Linctus may cause drowsiness in certain individuals and may therefore interfere with the ability to drive and to operate machinery.



4.8 Undesirable Effects



May cause constipation if used over a long period. If hypersensitive to squill could cause violent purging, nausea, vomiting and drowsiness.



4.9 Overdose



Nausea, vomiting, constipation, drowsiness – signs of morphine overdose. Treat by aspiration and lavage. In severe cases of overdosage morphine-induced depression may be reversed with the specific opiate antagonist naloxone. Intoxication due to squill glycosides, treat as for digoxin overdose.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Tincture of opium has a suppressant action on the cough centre due to its morphine and codeine content. Squill facilitates removal of mucus from bronchial passageways by virtue of a reflex action on bronchial secretions resulting from irritation of the gastrointestinal tract.



5.2 Pharmacokinetic Properties



Opioids are readily absorbed from the gastrointestinal tract, and undergo significant first pass metabolism in the liver. The major pathway for detoxification is conjugation with glucuronic acid. Very little morphine is excreted unchanged, it is eliminated by glomerular filtration. 90% of an administered dose is excreted within 24 hours. Codeine is likewise excreted chiefly in the urine.



5.3 Preclinical Safety Data



There are no preclinical data of relevance to the prescriber which are additional to that already included.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Tolu flavour solution



Liquid sugar



Honey



Alcohol (96%)



Benzoic acid



Racemic camphor



Star anise oil



Tragacanth powdered



Purified water



6.2 Incompatibilities



None stated.



6.3 Shelf Life



36 months.



6.4 Special Precautions For Storage



None



6.5 Nature And Contents Of Container



100, 200, 2000ml amber-coloured glass bottle with a polypropylene screw cap, unfitted or an aluminium pilfer-proof, roll-on cap and a PVC flowed-in liner or a triseal (LDPE/EPE/LDPE) liner.



6.6 Special Precautions For Disposal And Other Handling



Not applicable



7. Marketing Authorisation Holder



The Boots Company PLC



1 Thane Road West



Nottingham NG2 3AA



8. Marketing Authorisation Number(S)



PL00014/5721R



9. Date Of First Authorisation/Renewal Of The Authorisation



Date of first authorisation: 21 July 1989



Renewal of the authorisation: 29 September 2002



10. Date Of Revision Of The Text



January 2010




No comments:

Post a Comment